在生命末期，化疗往往没有帮助，而早期姑息治疗能改善生活质量，甚至延长生存期（Temel 2010）。
原始表述
أثبت تيميل (NEJM 2010) أن الرعاية التلطيفية المبكرة لسرطان الرئة المنتشر تحسّن جودة الحياة وتُطيل البقيا (11.6 شهراً مقابل 8.9) رغم تخفيف العلاج الكيماوي
非原话——为转述. 译文由本项目提供；以阿拉伯语原文为准。
译文
在生命末期，化疗往往没有帮助，而早期姑息治疗能改善生活质量，甚至延长生存期（Temel 2010）。
出处
- 来源状态
- 档案网站编辑
- 归属
- Archive editors (rule page summary/narrative)
- 出处
- https://eltayebat.com/rule/chemo-radiation/
- 归属的不确定性
- Written by archive operators; not attributed to Elawady.
- 涉及人群
Patients with metastatic or end-stage cancer
- Elawady 设定的地域限制
none found
科学评估
基本正确 – 核心内容正确，但有局限或细微不准确之处。
证据确定性: 低 – 进一步研究很可能大幅改变该评估。
1. 说法是什么？
Early palliative care improves QoL and prolongs survival despite less aggressive chemotherapy; chemo near death does not improve quality of death.
2. 哪些内容可证实是正确的？
Temel's RCT: better QoL (FACT-L 98.0 vs 91.5), fewer depressive symptoms, less aggressive end-of-life care, median survival 11.6 vs 8.9 months (A-CHM-16). Chemotherapy near death did not improve, and in fit patients worsened, quality of death (A-CHM-17); end-of-life overuse is a recognised issue (A-CHM-18).
3. 哪些内容是错误或夸大的？
'Proved ... prolonged survival' overstates the evidence: in Temel's trial survival was a secondary endpoint, and the Cochrane review found the survival effect of early palliative care uncertain (HR 0.85, 95% CI 0.56-1.28; very low certainty; I-CHM-104), while another meta-analysis found a benefit (I-CHM-128). The abstract reports less aggressive end-of-life care, not generally less chemotherapy; both arms received standard oncologic care, and guidelines recommend palliative care concurrent with active treatment (I-CHM-105). In advanced disease, chemotherapy still prolongs life for fit patients (non-small-cell lung cancer: 1-year survival 20% to 29%; I-CHM-103). These data concern metastatic or end-stage disease and do not apply to curative treatment.
4. 哪些内容仍不明确？
Mechanism of the survival effect.
5. 哪些研究支持该说法？
A-CHM-16, A-CHM-17, A-CHM-18; I-CHM-128 (1-year survival 56% vs 42% with outpatient specialty palliative care in three high-quality RCTs); I-CHM-104 (quality of life SMD 0.27, low certainty).
6. 哪些研究与该说法相矛盾？
Survival part: I-CHM-104 (Cochrane: survival effect uncertain). Scope: I-CHM-103 (chemotherapy prolongs survival in advanced NSCLC for fit patients); for curative settings I-CHM-01, I-CHM-02. I-CHM-105 (ASCO: palliative care concurrent with, not instead of, active treatment).
7. 对德国和欧洲而言情况如何？
Early palliative care integration is recommended in European oncology (not audited here).
8. 关于埃及的已知情况是什么？
Palliative-care availability may be limited (no data reviewed).
9. 合理的实际结论是什么？
尽早要求在抗癌治疗的同时获得姑息/支持治疗；在接近生命末期时讨论照护目标。
评估详情
- 证据确定性的依据
One RCT (Temel; survival a secondary endpoint) and observational data on end-of-life chemotherapy. The Cochrane review of early palliative care (I-CHM-104) rates the quality-of-life benefit as low-certainty and the survival effect as very low-certainty (HR 0.85, 0.56-1.28); a smaller meta-analysis of three high-quality trials found higher 1-year survival (56% vs 42%; I-CHM-128). The syntheses overlap and disagree on survival.
- 来源质量
Correct numbers; overstated wording.
- 地区可推广性
Moderate.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
仅在特定条件下成立 – 该说法仅在特定剂量、特定人群、特定制备方式或特定情况下成立。
研究问题: In patients with advanced incurable cancer, does chemotherapy near the end of life often fail to help, and does early palliative care improve quality of life and survival?
研究问题详解 (PICO)
- 人群
- Adults with advanced/metastatic cancer
- 干预或暴露
- Early palliative care; chemotherapy near death
- 对照
- Usual oncology care; no chemotherapy
- 地域范围
- universal; service availability varies
- 结局指标
- Quality of life
- Survival
- Quality of death
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Early palliative care helps patients with advanced lung cancer
RCT in metastatic NSCLC: early palliative care improved quality of life and mood; median survival longer.
- 实际结果
- FACT-L 98.0 vs 91.5; survival 11.6 vs 8.9 months (secondary)
- 方法学质量
- moderate (single-centre RCT)
- 相关性
- direct
- 局限
- Survival secondary endpoint; n=151
Chemotherapy in the last months of life did not improve quality of dying
Prigerson HG et al.. JAMA Oncol 2015 · PMID 26203912 · DOI 10.1001/jamaoncol.2015.2378 队列研究全文，含结构化偏倚风险评估Chemotherapy in the last months of life did not prolong survival and worsened quality of death in fitter patients.
- 实际结果
- Survival aHR 0.85 (0.65-1.11); ECOG 1 better quality of death 43.7% vs 68.6%
- 方法学质量
- moderate (prospective cohort)
- 相关性
- direct
- 局限
- Confounding by indication
Palliative care and survival: a meta-analysis
Meta-analysis of high-quality RCTs: specialty palliative care alongside oncology care improved 1-year survival and quality of life.
- 实际结果
- 1-year survival 56% vs 42%; QoL g=0.18
- 方法学质量
- moderate (3 RCTs for survival)
- 相关性
- direct
- 局限
- Few trials; conflicts with Cochrane
哪些证据不支持该说法？
Cochrane review: early palliative care in advanced cancer
Haun MW et al.. Cochrane Database Syst Rev 2017 · PMID 28603881 · DOI 10.1002/14651858.CD011129.pub2 Meta分析已核查摘要新增Cochrane review: quality-of-life benefit small; survival effect uncertain.
- 实际结果
- QoL SMD 0.27 (low certainty); survival HR 0.85 (0.56-1.28; very low)
- 方法学质量
- high (Cochrane)
- 相关性
- direct
- 局限
- Few trials
Chemotherapy vs supportive care alone in advanced lung cancer
NSCLC Meta-Analyses Collaborative Group. J Clin Oncol 2008 · PMID 18678835 · DOI 10.1200/JCO.2008.17.7162 Meta分析已核查摘要新增IPD meta-analysis: chemotherapy prolonged survival in advanced NSCLC for fit patients.
- 实际结果
- HR 0.77; 1-year survival 20% -> 29%
- 方法学质量
- high (IPD MA of RCTs)
- 相关性
- direct (limits 'chemo often does not help' to the end of life)
- 局限
- Older regimens
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Early palliative care, given alongside oncology care, improves quality of life (small effect); a survival benefit is possible but uncertain. Chemotherapy in the last weeks of life, especially in frail patients, often does not help; earlier in advanced disease it prolongs life for fit patients.
为什么有些研究权重更大
Cochrane (GRADE) weighs most for palliative care; IPD meta-analysis for chemotherapy benefit; overlapping syntheses not counted twice.
因果关系是否已确立？ 很可能 Randomised evidence for quality of life; survival evidence inconsistent.
仍存在的不确定性
Whether early palliative care prolongs survival; how to identify patients for whom chemotherapy no longer helps.
合理的结论
Mostly true within its scope (end of life, advanced disease); the 'even survival' part is uncertain; none of it applies to curative treatment.
为什么研究结果看起来互相矛盾？
Hoerger (survival benefit) vs Haun (uncertain): different trial selection (high-quality outpatient specialty trials vs all early palliative care trials), fixed time-point vs hazard ratio; overlapping trial pool, so not independent.
这是否取决于国家？
- 一般生物学效应
- Universal clinical evidence; palliative-care availability differs between countries.
- 饮食习惯
- Not relevant.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant.
- 本国生产条件
- Not relevant.
- 法律规则
- Not relevant.
- 实际监测数据
- Palliative-care service availability in Egypt was not reviewed.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Proportional-hazards consistency – 0.20^0.77 = 0.29 matches reported 1-year survival; NNT about 11 已重新计算
- Precision of survival HR – HR 0.85 (0.56-1.28) symmetric on log scale, very imprecise 已重新计算
- Absolute effect; overlap – 1-year survival +14 points (NNT about 7); same small pool of trials as I-CHM-104, so not an independent confirmation 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Survival with early palliative care
- 起始等级
- 高（随机试验）
- 降级理由
- imprecision
- inconsistency
- risk of bias (unblinded)
- 结果
- 低
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ASCO: Integration of Palliative Care Into Standard Oncology Care: ASCO Clinical Practice Guideline Update (Ferrell BR et al., J Clin Oncol 2017; I-CHM-105) (2017) · 原始文献
Patients with advanced cancer should receive dedicated palliative care services early in the disease course, concurrent with active treatment (read from the PubMed abstract; publisher page returned HTTP 403). - WHO: Cancer - fact sheet (2026 (page fetched 2026-10-26)) · 原始文献
Many cancers can be cured if detected early and treated effectively; treatment usually includes surgery, radiotherapy and/or systemic therapy; some cancers such as testicular seminoma and childhood leukaemias and lymphomas have high cure rates with appropriate treatment even when spread; palliative care relieves symptoms in advanced cancer.
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| Europe PMC | 2026年10月26日 | TITLE:"early palliative care" AND TITLE:"advanced cancer" AND JOURNAL:"Cochrane Database Syst Rev" | 双向 | 1 | |
| Europe PMC | 2026年10月26日 | TITLE:"palliative care" AND TITLE:"survival" AND TITLE:"meta-analysis" AND (TITLE:"early" OR TITLE:"specialist") AND PUB_YEAR:[2019 TO 2026] | 支持性证据 | 0 | |
| PubMed | 2026年10月26日 | ("early palliative care"[ti] OR "palliative care"[ti]) AND (survival[ti]) AND (randomized[ti] OR randomised[ti] OR trial[ti]) AND (cancer[ti]) | 支持性证据 | 1 | |
| Europe PMC | 2026年10月26日 | TITLE:"chemotherapy" AND (TITLE:"end of life" OR TITLE:"last days" OR TITLE:"near death" OR TITLE:"last 30 days") AND PUB_YEAR:[2014 TO 2026] AND (TITLE:"survival" OR TITLE:"quality") | 支持性证据 | 6 | |
| Europe PMC | 2026年10月26日 | TITLE:"chemotherapy" AND TITLE:"supportive care" AND TITLE:"non-small-cell lung cancer" AND (TITLE:"meta-analysis" OR TITLE:"individual patient") | 反对性证据 | 3 | |
| Europe PMC | 2026年10月26日 | TITLE:"Integration of Palliative Care Into Standard Oncology Care" | 指南 | 7 | |
| PubMed | 2026年10月26日 | "Integration of Palliative Care Into Standard Oncology Care"[ti] AND Ferrell BR[au] | 指南 | 0 |
待解决的问题
Survival effect of early palliative care in larger trials; availability of palliative care in Egypt.
核查深度如何？
7 项相关研究：1 项核查了全文（其中 1 项进行了结构化偏倚风险评估），6 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 基本正确 (中)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 评定结论已更改: 基本正确 (中) → 基本正确 (低)
Verdict unchanged. Certainty lowered to low: the Cochrane review rates the quality-of-life evidence as low and the survival evidence as very low certainty, and two overlapping meta-analyses disagree on survival.
新来源: I-CHM-104 I-CHM-128 I-CHM-103 I-CHM-105
通俗解释
对于晚期癌症，在抗癌治疗的同时尽早加入专业的姑息治疗，能使生活质量略有改善，并有助于缓解症状。一些研究提示患者的生存期也会延长，但这一点并不确定。在生命最后几周进行化疗往往没有帮助。在晚期疾病的较早阶段，化疗仍能为身体状况较好的患者争取更多时间。这些都不意味着化疗在较早的、可治愈的阶段是无用的。
与该说法相关的研究
支持该说法的研究 (4)
-
Early palliative care helps patients with advanced lung cancer
Temel JS et al.. N Engl J Med 2010 · PMID 20818875 · DOI 10.1056/NEJMoa1000678随机对照试验被 Tayebat 档案网站引用已核查摘要★ 关键研究Better quality of life, less depression, and longer median survival (11.6 vs 8.9 months) when added to cancer care.
Early palliative care benefit
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test early palliative care.
- 研究是如何开展的？
RCT.
- 研究了多少人、动物或样本？
151 patients.
- 实际发现了什么？
QoL and mood better; survival longer.
- 观察到的效应有多大？
+2.7 months median (11.6 vs 8.9 months; calculated).
- 研究结果对日常生活意味着什么？
Ask early for palliative/supportive care.
- 该研究有哪些局限？
Small single-centre trial.
- 它对 Elawady 的具体说法说明了什么？
Supports palliative care, not refusal of oncology.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
That chemotherapy is useless.
-
Chemotherapy in the last months of life did not improve quality of dying
Prigerson HG et al.. JAMA Oncol 2015 · PMID 26203912 · DOI 10.1001/jamaoncol.2015.2378队列研究被 Tayebat 档案网站引用全文，含结构化偏倚风险评估In patients still fit, chemotherapy near death was linked to worse quality of the last week.
End-of-life chemo
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Assess end-of-life chemo.
- 研究是如何开展的？
Prospective cohort.
- 研究了多少人、动物或样本？
312.
- 实际发现了什么？
No survival or QoD benefit.
- 观察到的效应有多大？
OR 0.35 (ECOG 1).
- 研究结果对日常生活意味着什么？
Discuss goals of care near end of life.
- 该研究有哪些局限？
Not randomised; chemotherapy users were younger and fitter; only patients who died were analysed; no dose data; caregiver-rated outcome.
- 它对 Elawady 的具体说法说明了什么？
Supports for end-stage only.
- 研究结果是否适用于德国和欧洲？
Moderate.
- 从该研究中明确不能得出什么结论？
That chemotherapy is harmful in curative, adjuvant or first-line settings; that chemotherapy never prolongs life in advanced cancer.
-
Too much chemotherapy close to death is a recognised problem
Earle CC et al.. J Clin Oncol 2008 · PMID 18688053 · DOI 10.1200/JCO.2007.15.8253叙述性综述被 Tayebat 档案网站引用已核查摘要Review of chemotherapy overuse and late hospice referral in the USA.
End-of-life overuse
该研究是否支持这一具体说法？ 是 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Review end-of-life care.
- 研究是如何开展的？
Narrative.
- 实际发现了什么？
Overuse trends.
- 研究结果对日常生活意味着什么？
Plan end-of-life care early.
- 该研究有哪些局限？
Narrative.
- 它对 Elawady 的具体说法说明了什么？
Supports end-of-life point only.
- 研究结果是否适用于德国和欧洲？
Low-moderate.
- 从该研究中明确不能得出什么结论？
Curative-setting conclusions.
-
Palliative care and survival: a meta-analysis
Hoerger M et al.. Ann Behav Med 2019 · PMID 30265282 · DOI 10.1093/abm/kay077Meta分析独立交叉核查已核查摘要In three good-quality trials, patients with palliative care alongside cancer treatment were more often alive after one year (56% vs 42%).
Specialty palliative care (concurrent with oncology care) associated with higher 1-year survival in 3 high-quality RCTs.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Measure palliative care effect on survival
- 研究是如何开展的？
Meta-analysis of RCTs
- 研究了多少人、动物或样本？
646 patients for survival
- 实际发现了什么？
Longer survival, better quality of life
- 观察到的效应有多大？
56% vs 42% alive at 1 year
- 研究结果对日常生活意味着什么？
Palliative care added to treatment may help people live longer and better
- 该研究有哪些局限？
Few trials; conflicts with Cochrane
- 它对 Elawady 的具体说法说明了什么？
Partly supports the claim
- 研究结果是否适用于德国和欧洲？
Moderate
- 从该研究中明确不能得出什么结论？
Does not mean stopping cancer treatment
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (2)
-
Cochrane review: early palliative care in advanced cancer
Haun MW et al.. Cochrane Database Syst Rev 2017 · PMID 28603881 · DOI 10.1002/14651858.CD011129.pub2Meta分析独立交叉核查已核查摘要★ 关键研究Early palliative care slightly improved quality of life and symptoms; any survival effect is uncertain.
Quality-of-life benefit confirmed (small); the 'even survival' part is not confirmed (HR 0.85, 0.56-1.28, very low certainty).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Summarise trials of early palliative care
- 研究是如何开展的？
Cochrane systematic review
- 研究了多少人、动物或样本？
7 trials, 1614 adults
- 实际发现了什么？
Small quality-of-life gain; survival unclear
- 观察到的效应有多大？
QoL SMD 0.27; survival HR 0.85 (0.56-1.28)
- 研究结果对日常生活意味着什么？
Palliative care helps people feel better; it is given alongside, not instead of, cancer treatment
- 该研究有哪些局限？
Few, unblinded trials
- 它对 Elawady 的具体说法说明了什么？
Supports the quality-of-life part; does not confirm longer survival
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Cannot show that palliative care replaces anticancer treatment
-
Chemotherapy vs supportive care alone in advanced lung cancer
NSCLC Meta-Analyses Collaborative Group. J Clin Oncol 2008 · PMID 18678835 · DOI 10.1200/JCO.2008.17.7162Meta分析独立交叉核查已核查摘要★ 关键研究Chemotherapy raised 1-year survival from 20% to 29%.
Chemotherapy prolongs life in advanced disease when patients are fit; 'often does not help' applies near death, not to advanced cancer in general.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Measure survival benefit of chemotherapy in advanced lung cancer
- 研究是如何开展的？
IPD meta-analysis of randomised trials
- 研究了多少人、动物或样本？
2714 patients in 16 trials
- 实际发现了什么？
23% lower risk of death
- 观察到的效应有多大？
HR 0.77; 1-year survival 20% -> 29%
- 研究结果对日常生活意味着什么？
About 1 in 11 treated patients is alive at 1 year because of chemotherapy
- 该研究有哪些局限？
Older drugs; modest absolute gain
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'oncology only buys time' as meaningless and 'chemo often does not help' in fit patients
- 研究结果是否适用于德国和欧洲？
High
- 从该研究中明确不能得出什么结论？
Does not show benefit for frail patients in their last weeks
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (1)
-
ASCO guideline: palliative care alongside cancer treatment
Ferrell BR et al.. J Clin Oncol 2017 · PMID 28034065 · DOI 10.1200/JCO.2016.70.1474指南 / 立场声明独立交叉核查已核查摘要Patients with advanced cancer should get palliative care early, together with active treatment.
Supports early palliative care; specifies it is concurrent with active treatment, which limits any reading as a reason to stop treatment.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Give guidance on palliative care
- 研究是如何开展的？
Guideline based on a systematic review
- 研究了多少人、动物或样本？
Trials 2010-2016
- 实际发现了什么？
Early, concurrent palliative care recommended
- 观察到的效应有多大？
Not applicable
- 研究结果对日常生活意味着什么？
Palliative care is an addition to cancer treatment
- 该研究有哪些局限？
US-based expert panel
- 它对 Elawady 的具体说法说明了什么？
Supports palliative care; contradicts using it as a reason to refuse treatment
- 研究结果是否适用于德国和欧洲？
Moderate
- 从该研究中明确不能得出什么结论？
Not a trial
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
Early palliative care integration is recommended in European oncology (not audited here).
埃及
Palliative-care availability may be limited (no data reviewed).
在我的国家适用什么？
一般科学评估
基本正确 对于接近生命末期的晚期、无法治愈的癌症，该说法基本正确：在治疗的同时尽早开展姑息治疗能改善生活质量，而在最后几周进行化疗往往没有帮助；姑息治疗能否带来生存获益尚不确定，而且这些都不适用于根治性治疗。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Early palliative care for patients with metastatic non-small-cell lung cancer.. Temel JS et al.. N Engl J Med 2010 · PMID 20818875 · DOI 10.1056/NEJMoa1000678
- Chemotherapy Use, Performance Status, and Quality of Life at the End of Life.. Prigerson HG et al.. JAMA Oncol 2015 · PMID 26203912 · DOI 10.1001/jamaoncol.2015.2378
- Aggressiveness of cancer care near the end of life: is it a quality-of-care issue?. Earle CC et al.. J Clin Oncol 2008 · PMID 18688053 · DOI 10.1200/JCO.2007.15.8253
- Impact of Interdisciplinary Outpatient Specialty Palliative Care on Survival and Quality of Life in Adults With Advanced Cancer: A Meta-Analysis of Randomized Controlled Trials.. Hoerger M et al.. Ann Behav Med 2019 · PMID 30265282 · DOI 10.1093/abm/kay077
- Early palliative care for adults with advanced cancer.. Haun MW et al.. Cochrane Database Syst Rev 2017 · PMID 28603881 · DOI 10.1002/14651858.CD011129.pub2
- Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.. NSCLC Meta-Analyses Collaborative Group. J Clin Oncol 2008 · PMID 18678835 · DOI 10.1200/JCO.2008.17.7162
- Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update.. Ferrell BR et al.. J Clin Oncol 2017 · PMID 28034065 · DOI 10.1200/JCO.2016.70.1474